Functional Food Market Overhauls Around 22g Protein, GLP-1 and Gut Health

2 articles · Updated · WholeFoods Magazine · Jun 1

One in eight adults now take a GLP-1 drug, pushing food and beverage makers toward companion products that support muscle retention, gut comfort, skin health and metabolic wellness.
22 grams of protein in Starbucks' Coffee and Protein and 40 mg daily doses for UC-II collagen illustrate the shift toward multi-benefit products that combine protein, fiber, cognition, hydration or mobility support.
Nearly a third of energy-drink consumers surveyed said they now want focus, memory and sustained mental energy rather than just caffeine, widening demand for functional teas, waters and juices.
Retailers are seeing high-protein creamers, sodas, chips and cereals gain traction, while gut-health shots, collagen powders and convenient ready-to-eat protein formats also stand out.
Personalization is emerging as the next growth engine, with brands betting that clinically backed, clean-label products tailored to specific occasions or health needs will win share.

Sources

WholeFoods Magazine2d ago

Functional Food & Beverage Market Overhaul Driven by Protein, GLP-1, Gut Health, Personalization

foodingredientsfirst.com2d ago

Health-forward F&B: Ingredients move from better-for-you to “more per bite”

With GLP-1 drugs creating new nutritional needs, which companion products are scientifically essential versus simply clever marketing?

As Asia-Pacific leads this market, how will its traditional ingredients and wellness philosophies reshape global functional food trends?

Is the 'function stacking' trend a true health revolution or a distraction from the proven benefits of whole-food nutrition?

The GLP-1 Revolution: How Appetite-Suppressing Drugs Are Reshaping the $100B Functional Food Market in 2026

Overview

The rise of GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro is driving major changes in the food industry. These medications quiet persistent food cravings, leading people to eat more intentionally and choose smaller, nutrient-dense portions. As a result, food companies are rethinking their products to meet new expectations for nutrition, portion size, and experience. This shift is not just about reformulating foods, but about adapting to a new landscape where every bite counts. The impact of GLP-1 drugs is reshaping consumer habits and pushing the industry toward healthier, more purposeful offerings.

...